# Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet

> **NCT03074058** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 20 (actual)

## Conditions studied

- Clinical Pharmacology

## Interventions

- **DRUG:** Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)
- **DRUG:** Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)

## Key facts

- **NCT ID:** NCT03074058
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-10
- **Primary completion:** 2015-08-04
- **Final completion:** 2015-08-21
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074058, "Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03074058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*